Conventional type 1 dendritic cells in protective antitumor immunity and its potential in hepatocellular carcinoma

Abstract

Immunotherapy is revolutionizing the clinical management of cancer patients by modulating T cells and natural killer cells. Dendritic cells (DCs) have the capacity to orchestrate the expansion and function of these effector cells both in lymphoid and non-lymphoid tissues of cancer patients. Distinct subtypes of DCs have various capacities to prime and activate different T cell responses. Here, we review conventional type 1 dendritic cells (cDC1s) and their crucial role in protective anti-tumor immunity. Targeting cDC1s as a cancer vaccine against the development of hepatocellular carcinoma will be discussed.

Keywords

Conventional type 1 dendritic cells / antitumor immunity / hepatocellular carcinoma / cancer vaccine

References

[1] Chen DS.Elements of cancer immunity and the cancer-immune set point..Nature2017;541:321-30

[2] Friedrich MJ.Immunotherapy 2.0: improving the response to checkpoint inhibitors..JAMA2019;321:131-3

[3] Shankaran V,Bruce AT,Swanson PE.IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity..Nature2001;410:1107-11

[4] van Dinther D,van de Ven R,de Gruijl TD.Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines..J Leukoc Biol2017;102:1017-34 PMCID:PMC5597514

[5] Romero P,Bhardwaj N,Disis ML.The Human Vaccines Project: A roadmap for cancer vaccine development..Sci Transl Med2016;8:334ps9

[6] Muller WA.Migration of leukocytes across endothelium and beyond: molecules involved in the transmigration and fate of monocytes..J Leukoc Biol1999;66:698-704

[7] Jakubzick C,Gibbings SL,Schlitzer A.Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes..Immunity2013;39:599-610 PMCID:PMC3820017

[8] Yona S,Wolf Y,Varol D.Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis..Immunity2013;38:79-91 PMCID:PMC3908543

[9] Scott CL,De Baetselier P,Saeys Y.Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells..Nat Commun2016;7:10321 PMCID:PMC4737801

[10] Ramachandran P,Wilson-Kanamori JR,Henderson BEP.Resolving the fibrotic niche of human liver cirrhosis at single-cell level..Nature2019;575:512-8 PMCID:PMC6876711

[11] Naik SH,Park HY,Proietto AI.Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo..Nat Immunol2007;8:1217-26

[12] Onai N,Schmid MA,Jarrossay D.Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow..Nat Immunol2007;8:1207-16

[13] Palomino-Segura M,Farsakoglu Y,Latino I.Protection against influenza infection requires early recognition by inflammatory dendritic cells through C-type lectin receptor SIGN-R1..Nat Microbiol2019;4:1930-40 PMCID:PMC6817362

[14] Guilliams M,Jakubzick C,Onai N.Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny..Nat Rev Immunol2014;14:571-8 PMCID:PMC4638219

[15] Menezes S,Anselmi G,Loschko J.The Heterogeneity of Ly6Chi Monocytes Controls Their Differentiation into iNOS+ Macrophages or Monocyte-Derived Dendritic Cells..Immunity2016;45:1205-18 PMCID:PMC5196026

[16] Gautier EL,Miller J,Jakubzick C.Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages..Nat Immunol2012;13:1118-28 PMCID:PMC3558276

[17] Caminschi I,Ahmet F,Shin Teh J.The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement..Blood2008;112:3264-73 PMCID:PMC2569177

[18] Bonifaz LC,Charalambous A,Fujii S.In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination..J Exp Med2004;199:815-24 PMCID:PMC2212731

[19] Neubert K,Heger L,Staedtler AM.Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo..J Immunol2014;192:5830-8

[20] Dhodapkar MV,Zhao B,Carvajal RD.Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205..Sci Transl Med2014;6:232ra51 PMCID:PMC6151129

[21] Cruz FM,Merino E,Rock KL.The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules..Annu Rev Immunol2017;35:149-76 PMCID:PMC5508990

[22] den Haan JM,Bevan MJ.CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo..J Exp Med2000;192:1685-96 PMCID:PMC2213493

[23] Kitano M,Takumi A,Hemmi H.Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node..Proc Natl Acad Sci U S A2016;113:1044-9 PMCID:PMC4743831

[24] Cancel JC,Dalod M.Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?.Front Immunol2019;10:9 PMCID:PMC6379659

[25] Böttcher JP,Chakravarty P,Cabeza-Cabrerizo M.NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control..Cell2018;172:1022-1037.e14 PMCID:PMC5847168

[26] Schiavoni G,Sestili P,Venditti M.ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells..J Exp Med2002;196:1415-25 PMCID:PMC2194263

[27] Hacker C,Ju XS,Gust TC.Transcriptional profiling identifies Id2 function in dendritic cell development..Nat Immunol2003;4:380-6

[28] Hildner K,Purtha WE,Matsushita H.Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity..Science2008;322:1097-100 PMCID:PMC2756611

[29] Kashiwada M,Pewe LL,Rothman PB.NFIL3/E4BP4 is a key transcription factor for CD8α⁺ dendritic cell development..Blood2011;117:6193-7 PMCID:PMC3122942

[30] Bagadia P,Liu TT,Grajales-Reyes GE.An Nfil3-Zeb2-Id2 pathway imposes Irf8 enhancer switching during cDC1 development..Nat Immunol2019;20:1174-85 PMCID:PMC6707889

[31] Grajales-Reyes GE,Albring J,Tussiwand R.Batf3 maintains autoactivation of Irf8 for commitment of a CD8α(+) conventional DC clonogenic progenitor..Nat Immunol2015;16:708-17 PMCID:PMC4507574

[32] Poulin LF,Griessinger E,Craciun L.Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells..J Exp Med2010;207:1261-71 PMCID:PMC2882845

[33] Jongbloed SL,McDonald KJ,Ju X.Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens..J Exp Med2010;207:1247-60 PMCID:PMC2882828

[34] Dorner BG,Zhou X,Mora A.Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells..Immunity2009;31:823-33

[35] Crozat K,Contreras V,Dutertre CA.The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells..J Exp Med2010;207:1283-92 PMCID:PMC2882835

[36] Engelhardt JJ,Beemiller P,Sorensen C.Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells..Cancer Cell2012;21:402-17 PMCID:PMC3311997

[37] Broz ML,Boldajipour B,Pollack JL.Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity..Cancer Cell2014;26:638-52 PMCID:PMC4254577

[38] Salmon H,Rahman A,Remark R.Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition..Immunity2016;44:924-38 PMCID:PMC4980762

[39] Mittal D,Putz EM,Markey KA.Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis..Cancer Immunol Res2017;5:1098-108

[40] Chen K,Zhao H,Ge Y.XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti-PD-1 Efficacy..Cancer Immunol Res2020;8:81-93

[41] Barry KC,Broz ML,Binnewies M.A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments..Nat Med2018;24:1178-91 PMCID:PMC6475503

[42] Kastenmüller W,Wang Z,Egen JG.Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node..Immunity2013;38:502-13 PMCID:PMC3793246

[43] Spranger S,Horton B.Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy..Cancer Cell2017;31:711-23.e4 PMCID:PMC5650691

[44] Zhu AX,Edeline J,Ogasawara S.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial..Lancet Oncol2018;19:940-52

[45] El-khoueiry AB,Yau T,Kudo M.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502

[46] Sia D,Martinez-Quetglas I,Villacorta-Martin C.Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features..Gastroenterology2017;153:812-26

[47] Harding JJ,Armenia J,Albano M.Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies..Clin Cancer Res2019;25:2116-26 PMCID:PMC6689131

[48] Ruiz de Galarreta M,Molina-Sánchez P,Maier B.β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma..Cancer Discov2019;9:1124-41 PMCID:PMC6677618

[49] Di Tommaso L,Borzio M,Farinati F.Advanced precancerous lesions in the liver..Best Pract Res Clin Gastroenterol2013;27:269-84

[50] Grimm CF,Mohr L,Krohne TU.Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice..Gastroenterology2000;119:1104-12

[51] Hong Y,Guo ZS,Pang J.Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma..Hepatology2014;59:1448-58 PMCID:PMC4151349

[52] Geissler M,Weth R,Grimm CF.Immunotherapy directed against alpha-fetoprotein results in autoimmune liver disease during liver regeneration in mice..Gastroenterology2001;121:931-9

[53] Filmus J.Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma..FEBS J2013;280:2471-6